SARS-CoV-2 Spike Antagonizes Innate Antiviral Immunity by Targeting Interferon Regulatory Factor 3

被引:23
|
作者
Freitas, Raul S. [1 ]
Crum, Tyler F. [1 ]
Parvatiyar, Kislay [1 ]
机构
[1] Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave, New Orleans, LA 70112 USA
关键词
SARS-CoV-2; IRF3; interferon; RIG-I antiviral; innate immunity; I INTERFERON; PATHOGEN RECOGNITION; DEGRADATION; IRF3;
D O I
10.3389/fcimb.2021.789462
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Corona virus disease 2019 (COVID-19) pathogenesis is intimately linked to the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) and disease severity has been associated with compromised induction of type I interferon (IFN-I) cytokines which coordinate the innate immune response to virus infections. Here we identified the SARS-CoV-2 encoded protein, Spike, as an inhibitor of IFN-I that antagonizes viral RNA pattern recognition receptor RIG-I signaling. Ectopic expression of SARS-CoV-2 Spike blocked RIG-I mediated activation of IFN beta and downstream induction of interferon stimulated genes. Consequently, SARS-CoV-2 Spike expressing cells harbored increased RNA viral burden compared to control cells. Co-immunoprecipitation experiments revealed SARS-CoV-2 Spike associated with interferon regulatory factor 3 (IRF3), a key transcription factor that governs IFN-I activation. Co-expression analysis via immunoassays further indicated Spike specifically suppressed IRF3 expression as NF-kappa B and STAT1 transcription factor levels remained intact. Further biochemical experiments uncovered SARS-CoV-2 Spike potentiated proteasomal degradation of IRF3, implicating a novel mechanism by which SARS-CoV-2 evades the host innate antiviral immune response to facilitate COVID-19 pathogenesis.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] SARS-CoV-2 immunity
    Antonio Bertoletti
    Cellular & Molecular Immunology, 2024, 21 : 101 - 102
  • [42] SARS-CoV-2 immunity
    Bertoletti, Antonio
    CELLULAR & MOLECULAR IMMUNOLOGY, 2024, 21 (02) : 101 - 102
  • [43] Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents
    Ayaz, Sameer
    Crea, Francesco
    EPIGENOMICS, 2020, 12 (10) : 811 - 812
  • [44] Antiviral cyclic peptides targeting the main protease of SARS-CoV-2
    Johansen-Leete, Jason
    Ullrich, Sven
    Fry, Sarah E.
    Frkic, Rebecca
    Bedding, Max J.
    Aggarwal, Anupriya
    Ashhurst, Anneliese S.
    Ekanayake, Kasuni B.
    Mahawaththa, Mithun C.
    Sasi, Vishnu M.
    Luedtke, Stephanie
    Ford, Daniel J.
    O'Donoghue, Anthony J.
    Passioura, Toby
    Larance, Mark
    Otting, Gottfried
    Turville, Stuart
    Jackson, Colin J.
    Nitsche, Christoph
    Payne, Richard J.
    CHEMICAL SCIENCE, 2022, 13 (13) : 3826 - 3836
  • [45] Design, production and characterization of antiviral proteins targeting SARS-CoV-2
    Parreiras, S.
    Cruz, C. H.
    Valerio, M.
    Sousa, P. M. F.
    Soares, C. M.
    Vicente, J. B.
    Lousa, D.
    FEBS OPEN BIO, 2022, 12 : 160 - 160
  • [46] The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
    Aliyari, Saba R.
    Quanquin, Natalie
    Pernet, Olivier
    Zhang, Shilei
    Wang, Lulan
    Cheng, Genhong
    PATHOGENS, 2022, 11 (05):
  • [47] Type I Interferon Shapes Humoral Immunity to SARS-CoV-2
    Goldman-Israelow, Benjamin
    Mao, Tianyang
    Song, Eric
    Lu, Peiwen
    Wong, Patrick
    Lucas, Carolina
    Klein, Jon
    Iwasaki, Akiko
    JOURNAL OF IMMUNOLOGY, 2021, 206
  • [48] The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity
    Stewart, Hazel
    Lu, Yongxu
    O'Keefe, Sarah
    Valpadashi, Anusha
    Cruz-Zaragoza, Luis Daniel
    Michel, Hendrik A.
    Nguyen, Samantha K.
    Carnell, George W.
    Lukhovitskaya, Nina
    Milligan, Rachel
    Adewusi, Yasmin
    Jungreis, Irwin
    Lulla, Valeria
    Matthews, David A.
    High, Stephen
    Rehling, Peter
    Emmott, Edward
    Heeney, Jonathan L.
    Davidson, Andrew D.
    Edgar, James R.
    Smith, Geoffrey L.
    Firth, Andrew E.
    ISCIENCE, 2023, 26 (11)
  • [49] ‘Prime and spike’ induces mucosal immunity and reduces SARS-CoV-2 transmission
    Alexandra Flemming
    Nature Reviews Immunology, 2022, 22 : 718 - 718
  • [50] 'Prime and spike' induces mucosal immunity and reduces SARS-CoV-2 transmission
    Flemming, Alexandra
    NATURE REVIEWS IMMUNOLOGY, 2022, 22 (12) : 718 - 718